The biggest conceptual research objections for the patient’s well-being would be the extensively research findings of the association of elevated selenium in patients who later developed diabetes or diabetes-related symptoms. The first such findings were reported by Strange et al in August of 2007.1
An analysis of a randomized, double-blind placebo-controlled trial involved 1,202 patients with skin cancer, excluding melanoma patients. The subjects were chosen from areas where people often had low blood selenium. Participants’ blood was tested for selenium and then patients were supplemented with 200 micrograms of selenium in a baker’s yeast tablet daily, or a placebo (provided by Nutrition 21). Patients were followed for 7.7 years. The cumulative incidence of type 2 diabetes was higher among those receiving selenium than for those receiving placebo. A significant increased risk for type 2 diabetes was observed in the top tertial (top grouping highest in selenium).










0 Comments